JOHN L. DECKER, M.D., F.A.C.P.; JOHN H. KLIPPEL, M.D.; PAUL H. PLOTZ, M.D.; ALFRED D. STEINBERG, M.D.
▸Requests for reprints should be addressed to John L. Decker, M.D., Bldg. 10, Room 9N218, National Institutes of Health, Bethesda, MD 20014.
DECKER JL, KLIPPEL JH, PLOTZ PH, STEINBERG AD. Cyclophosphamide or Azathioprine in Lupus Glomerulonephritis: A Controlled Trial: Results at 28 Months. Ann Intern Med. 1975;83:606-615. doi: 10.7326/0003-4819-83-5-606
Download citation file:
Published: Ann Intern Med. 1975;83(5):606-615.
Thirty-eight patients with diffuse glomerulonephritis of systemic lupus erythematosus were randomly assigned to add cyclophosphamide, azathioprine, or nothing to low-dose corticosteriod treatment and have been followed for a mean of 2⅓ years thereafter. Of the 11 patients with unfavorable outcomes (8 deaths and 3 beginning hemodialyses), 2 occurred on cyclophosphamide, 4 on azathioprine, and 5 on prednisone only. Deaths due to infection occurred on the cytotoxics, while deaths ascribed to central nervous system lupus erythematosus occurred exclusively on prednisone only. Gradual deterioration of renal function was observed in all three groups, most frequently on prednisone only. Undesirable events, some due to drugs, were observed. At the time of reporting, the cytotoxic agents seemed to add marginally to the control of the disease; other treatment schedules should be evaluated.
Learn more about subscription options.
Register Now for a free account.
Nephrology, Rheumatology, Autoimmune Kidney Disease, Lupus Erythematosus.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only